You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Chaudhri A, Bu X, Wang Y, et al
808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0808